AbCellera Biologics, Inc
2.93 %
-41.71 %
Yet to be announced
Company Overview
AbCellera Biologics, Inc. is a technology company that conducts antibody drug discovery for pharmaceutical partners. The company uses an integrated platform combining microfluidics, genomics, AI, machine learning, and other technologies to identify and develop antibody treatments. Their platform enables the rapid discovery of therapeutic antibodies from natural immune responses.
The company partners with pharmaceutical companies to discover and develop antibodies for various diseases and conditions. Their technology has been particularly notable in developing COVID-19 antibody treatments, though their platform is applicable across many therapeutic areas.
Revenue Sources
PassAbCellera's revenue primarily comes from research and development partnerships, milestone payments, and royalties from antibody discovery and development. Their core business involves legitimate medical research and development of therapeutic antibodies. There is no evidence of revenue from prohibited sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2024 | $5.05m | $77.8m | - | - | 0.00% | 0.00% |
| Sept. 30, 2024 | $6.51m | $100.17m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $7.32m | $100.78m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $9.95m | $64.85m | - | - | 0.00% | 0.00% |
Based on the financial data provided for the last four quarters, AbCellera reported zero interest income and zero interest expense. The company appears to operate without significant interest-bearing debt or interest-generating investments. The company is in its operational phase with established revenue streams, making this assessment valid.
Operational Ethics
PassAfter reviewing company documents, press releases, and public information, there is no evidence of current material associations with the state of Israel or the Chinese Communist Party. The company's primary operations and research facilities are located in Canada and the United States.
Comments